To our knowledge, this study is the first to evaluate the cost-effectiveness of ZOL-FO as the first-line treatment option for patients with CLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma, and its results will be instructive in China and other countries, which is the most important innovative point of this study. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.